A carregar...
Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia
In sickle cell disease (SCD), hydroxyurea (HU) treatment decreases the number of vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) by increasing fetal hemoglobin (HbF). Data are lacking regarding the frequency of HU dose modification or whether sub-therapeutic doses (<15 mg/kg/day) are b...
Na minha lista:
| Publicado no: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5877542/ https://ncbi.nlm.nih.gov/pubmed/29495591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms19030681 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|